Clinical Trials Logo

Clinical Trial Summary

As most of the upper airways infections (UAI) leading to wheezing are secondary to viral triggers, the possible antinflammatory and antiviral role of resveratrol has been suggested in several studies, both in vitro and in vivo. However, its efficacy has been studied only when evaluating upper respiratory symptoms. With the aim to define new approaches in patients with recurrent wheezing triggered by UAI we have performed a prospective observational study to evaluate the efficacy of a short-course of intranasal resveratrol, administered for 7 days at the beginning of UAI, when compared to standard nasal lavage with 0.9% saline solution, in terms of reduction in wheezing episodes.


Clinical Trial Description

Patients Patients were selected from those referring to our centre for recurrent wheezing in the previous year. The inclusion criteria were: - Presence of at least 8 episodes of wheezing in the previous October-March period - Negative skin prick test (SPT) for the most common allergens. - Age less than 6 years The exclusion criteria were: - Sensitization to food allergens - Sensitization to perennial allergens or to tree pollen allergens. - Presence of atopic dermatitis Patients were enrolled during visit 1, from April to August 2018, and were instructed to record symptoms of upper and lower airways during the wash-out period of September. During visit 2 at the end of September patients were randomized into 2 groups: - group 1: patients treated with 0.9% saline solution daily nasal lavage - group 2: patients treated with 0.9% saline solution daily nasal lavage and a 7-days therapy with nasal resveratrol, from the beginning of upper airways symptoms. All patients were followed from September 2018 to the end of March 2019, with visit 3 and 4 after two (end of November) and four months (end of January). Follow-up ended with visit 5 at the end of March. All patients were instructed to register in specifically designated charts the number of days with symptoms of upper airways inflammation and the recurrence of wheezing. As predictive index of disease severity, parents were instructed to register both days with oral corticosteroids administration (OCA) and with hospitalization need, as ER occurrence or admission to paediatric wards. All patient were instructed to treat each wheezing episode with inhaled salbutamol and, if wheezing persisted, with oral prednisolone once a day, according to guidelines (Gina 2015). Skin prick tests The sensitization status of each patient was assessed by performing skin prick tests (SPTs) with a standard panel of environmental (Stallergenes, Antony, France) and food allergens (Lofarma, Milan, Italy). Positivity of SPT was established according to the guidelines of the European Academy of Allergology and Clinical Immunology. The standard panel of allergens included Phleum pratense, Parietaria judaica, Juniperus ashei, Olea europaea, Dermatophagoides pteronyssinus, Alternaria tenuis, cat and dog epithelium; milk, egg, peanut, tree nuts, fish, shellfish, soy, and wheat plus a positive (histamine 10 mg/mL) and a negative (normal saline) control. Wheals were contoured with a soft pen and transferred onto cellotape. A skin reaction of 5 mm was considered the threshold for positivity. Clinical symptoms, rescue medication and severity evaluation During the evaluation period, patients filled in daily diary cards to record days with symptoms involving the upper (sneezing, rhinorrhoea, itching and nasal blockage) and lower airways (cough, dyspnoea and wheezing), the use of oral corticosteroids (OCS) and the days of hospitalization when occurred. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04689412
Study type Observational
Source University Of Perugia
Contact
Status Completed
Phase
Start date April 1, 2018
Completion date April 30, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04669288 - AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Phase 3
Withdrawn NCT04584034 - Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial Phase 4
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Enrolling by invitation NCT00775697 - Montelukast in Children With Wheezing Phase 4
Completed NCT00749528 - Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing N/A
Recruiting NCT00494624 - Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Phase 4
Recruiting NCT04128592 - Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers N/A
Recruiting NCT06093152 - Video Assisted Study of Salbutamol Response in Viral Wheezing
Completed NCT01452945 - Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing N/A
Withdrawn NCT00628303 - A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants Phase 3
Completed NCT01028560 - Allergy Immunotherapy for the Reduction of Asthma Phase 1/Phase 2
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00507676 - Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing N/A
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Recruiting NCT06106646 - Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
Recruiting NCT05710081 - Bacterial Lysate In Preventing Asthma Phase 3
Completed NCT04011709 - A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy Early Phase 1
Active, not recruiting NCT03377192 - Impedance Pneumography in Assessment of Asthma Control in Preschool Children
Completed NCT01142505 - Wheeze and Intermittent Treatment Phase 3
Active, not recruiting NCT04942483 - Using Specific Tests in Preschool Children With Wheeze to Help us Determine the Necessity of Inhaled Corticosteroid Therapy (Feasibility Study).